{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:58:33Z","timestamp":1789203513487,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:00Z","timestamp":1494633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40259-017-0225-6","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T03:52:25Z","timestamp":1494647545000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches"],"prefix":"10.1007","volume":"31","author":[{"given":"Emilie","family":"Cayssials","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,13]]},"reference":[{"issue":"15","key":"225_CR1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451\u201364.","journal-title":"N Engl J Med"},{"issue":"23","key":"225_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med."},{"issue":"6","key":"225_CR3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"11","key":"225_CR4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335.","journal-title":"Lancet Oncol."},{"issue":"1","key":"225_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11899-012-0148-8","volume":"8","author":"R Kinstrie","year":"2013","unstructured":"Kinstrie R, Copland M. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep. 2013;8(1):14\u201321.","journal-title":"Curr Hematol Malig Rep"},{"issue":"20","key":"225_CR6","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565\u201372.","journal-title":"Blood"},{"issue":"7240","key":"225_CR7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MAG Essers","year":"2009","unstructured":"Essers MAG, et al. IFN\u03b1 activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904\u20138.","journal-title":"Nature"},{"issue":"6","key":"225_CR8","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood.V88.6.2279.bloodjournal8862279","volume":"88","author":"BA Pierson","year":"1996","unstructured":"Pierson BA, Miller JS. CD56+ bright and CD56+ dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88(6):2279\u201387.","journal-title":"Blood"},{"issue":"4","key":"225_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ijc.2910430410","volume":"43","author":"WC Chang","year":"1989","unstructured":"Chang WC, Fujimiya Y, Casteel N, Pattengale P. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells. Int J Cancer. 1989;43(4):591\u20137.","journal-title":"Int J Cancer"},{"issue":"3","key":"225_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","volume":"26","author":"CI-U Chen","year":"2012","unstructured":"Chen CI-U, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2012;26(3):465\u201374.","journal-title":"Leukemia"},{"issue":"13","key":"225_CR11","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood.V98.13.3750","volume":"98","author":"M Mohty","year":"2001","unstructured":"Mohty M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98(13):3750\u20136.","journal-title":"Blood"},{"issue":"1","key":"225_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2002.03831.x","volume":"119","author":"M Mohty","year":"2002","unstructured":"Mohty M, et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+\/CD38\u2212 primitive haematopoietic progenitors. Br J Haematol. 2002;119(1):115\u20138.","journal-title":"Br J Haematol"},{"issue":"9","key":"225_CR13","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","volume":"101","author":"R Dong","year":"2003","unstructured":"Dong R, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 2003;101(9):3560\u20137.","journal-title":"Blood"},{"issue":"7","key":"225_CR14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/eji.201142043","volume":"42","author":"A Rossignol","year":"2012","unstructured":"Rossignol A, et al. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol. 2012;42(7):1870\u20135.","journal-title":"Eur J Immunol"},{"issue":"1","key":"225_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25(1):297\u2013336.","journal-title":"Annu Rev Immunol."},{"issue":"3","key":"225_CR16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.4779","volume":"240","author":"S Basbous","year":"2016","unstructured":"Basbous S, et al. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia. J Pathol. 2016;240(3):262\u20138.","journal-title":"J Pathol."},{"issue":"1","key":"225_CR17","doi-asserted-by":"crossref","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PloS One. 2013;8(1):e55818.","journal-title":"PloS One"},{"issue":"8","key":"225_CR18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384.","journal-title":"Nat Rev Drug Discov."},{"issue":"8","key":"225_CR19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528\u201336.","journal-title":"Blood"},{"key":"225_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107","volume":"5","author":"C Giallongo","year":"2015","unstructured":"Giallongo C, et al. Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol. 2015;5:107. doi: 10.3389\/fonc.2015.00107 .","journal-title":"Front Oncol"},{"issue":"11","key":"225_CR21","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/eji.201040895","volume":"40","author":"J-I Youn","year":"2010","unstructured":"Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40(11):2969.","journal-title":"Eur J Immunol."},{"issue":"1","key":"225_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells\u2014a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1(1):10.","journal-title":"J Immunother Cancer"},{"key":"225_CR23","doi-asserted-by":"crossref","unstructured":"Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3.","DOI":"10.3389\/fonc.2013.00049"},{"issue":"2","key":"225_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","volume":"129","author":"A Tarafdar","year":"2017","unstructured":"Tarafdar A, et al. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 2017;129(2):199\u2013208.","journal-title":"Blood"},{"issue":"9","key":"225_CR25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","volume":"124","author":"P Gallipoli","year":"2014","unstructured":"Gallipoli P, et al. JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014;124(9):1492\u2013501.","journal-title":"Blood"},{"issue":"1","key":"225_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-8722-7-37","volume":"7","author":"S Okabe","year":"2014","unstructured":"Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. J Hematol Oncol. 2014;7(1):37.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"225_CR27","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","volume":"74","author":"A Levescot","year":"2014","unstructured":"Levescot A, et al. BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res. 2014;74(10):2669\u201376.","journal-title":"Cancer Res."},{"issue":"23","key":"225_CR28","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang B, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood. 2016;128(23):2671\u201382.","journal-title":"Blood"},{"issue":"4760","key":"225_CR29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the BCR\/ABL hybrid gene. Science. 1986;233(4760):212\u20134.","journal-title":"Science"},{"issue":"1","key":"225_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","volume":"86","author":"JM Gerber","year":"2011","unstructured":"Gerber JM, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol. 2011;86(1):31.","journal-title":"Am J Hematol."},{"issue":"9","key":"225_CR31","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","volume":"87","author":"M Bocchia","year":"1996","unstructured":"Bocchia M, et al. Specific human cellular immunity to BCR-ABL oncogene-derived peptides. Blood. 1996;87(9):3587\u201392.","journal-title":"Blood"},{"issue":"3","key":"225_CR32","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2000.02090.x","volume":"109","author":"LC Norbury","year":"2000","unstructured":"Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol. 2000;109(3):616\u201321.","journal-title":"Br J Haematol."},{"issue":"14","key":"225_CR33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0264-410X(94)80052-2","volume":"12","author":"PO Livingston","year":"1994","unstructured":"Livingston PO, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 1994;12(14):1275\u201380.","journal-title":"Vaccine"},{"issue":"3","key":"225_CR34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, et al. A multivalent BCR-ABL fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037\u201342.","journal-title":"Blood"},{"issue":"9460","key":"225_CR35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365(9460):657\u201362.","journal-title":"Lancet"},{"issue":"11","key":"225_CR36","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21(11):2287\u201395.","journal-title":"Leukemia"},{"issue":"1","key":"225_CR37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236\u201342.","journal-title":"Blood"},{"issue":"5","key":"225_CR38","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","volume":"112","author":"C Quintarelli","year":"2008","unstructured":"Quintarelli C, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112(5):1876\u201385.","journal-title":"Blood"},{"issue":"21","key":"225_CR39","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","volume":"123","author":"L Dubrovsky","year":"2014","unstructured":"Dubrovsky L, et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 2014;123(21):3296\u2013304.","journal-title":"Blood"},{"issue":"3","key":"225_CR40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31(3):697\u2013704.","journal-title":"Leukemia"},{"key":"225_CR41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcmd.2016.11.001","volume":"62","author":"A Allegra","year":"2016","unstructured":"Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C. Adoptive immunotherapy for hematological malignancies: current status and new insights in chimeric antigen receptor T cells. Blood Cells Mol Dis. 2016;62:49\u201363.","journal-title":"Blood Cells Mol Dis."},{"issue":"8","key":"225_CR42","doi-asserted-by":"crossref","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, et al. Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-\u03b1 Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. PLOS One. 2011;6(8):e23022.","journal-title":"PLOS One"},{"issue":"12","key":"225_CR43","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","volume":"44","author":"FA Castro de","year":"2003","unstructured":"de Castro FA, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma. 2003;44(12):2061\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"225_CR44","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","volume":"30","author":"H Hjorth-Hansen","year":"2016","unstructured":"Hjorth-Hansen H, et al. Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30(9):1853\u201360.","journal-title":"Leukemia"},{"issue":"5","key":"225_CR45","doi-asserted-by":"crossref","first-page":"0155959","DOI":"10.1371\/journal.pone.0155959","volume":"11","author":"V Polivkova","year":"2016","unstructured":"Polivkova V, et al. Interferon-\u03b1 revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients. Plos One. 2016;11(5):0155959.","journal-title":"Plos One"},{"issue":"1","key":"225_CR46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17\u201323.","journal-title":"Blood"},{"issue":"5","key":"225_CR47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137.","journal-title":"J Clin Invest."},{"key":"225_CR48","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"issue":"8","key":"225_CR49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28(8):1429\u201335.","journal-title":"J Clin Oncol."},{"issue":"5","key":"225_CR50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol. 2014;32(5):415\u201323.","journal-title":"J Clin Oncol"},{"issue":"4","key":"225_CR51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31(4):829\u201336.","journal-title":"Leukemia"},{"issue":"2","key":"225_CR52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","volume":"35","author":"S Sopper","year":"2016","unstructured":"Sopper S, et al. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2016;35(2):175\u201384.","journal-title":"J Clin Oncol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0225-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T15:05:15Z","timestamp":1602083115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0225-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,13]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0225-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,13]]}}}